Viridian Therapeutics (VRDN) Earnings Date, Estimates & Call Transcripts $20.14 -1.50 (-6.93%) (As of 11/15/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Viridian Therapeutics Latest Earnings SummaryUpcoming Earnings DateFeb. 25EstimatedActual EPS (Nov. 12) -$1.15 Missed By -$0.04 Consensus EPS (Nov. 12) -$1.11 Viridian Therapeutics issued Q3 2024 earnings on November 12, 2024, reporting an EPS of -$1.15, which missed analysts' consensus estimates of -$1.11 by $0.04. Quarterly revenue was reported to be $0.09 million, above analyst estimates of $0.08 million. With a trailing EPS of -$4.31, Viridian Therapeutics' earnings are expected to decrease next year, from ($4.01) to ($4.28) per share. VRDN Upcoming EarningsViridian Therapeutics' next earnings date is estimated for Tuesday, February 25, 2025, based off prior year's reporting schedules. Get Viridian Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viridian Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataVRDN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.VRDN Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Darwin2024's Must-Watch Stocks!Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] Viridian Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20244-$0.99-$0.89-$0.93Q2 20245-$0.90-$0.80-$0.83Q3 20245-$1.14-$0.86-$1.03Q4 20245-$1.18-$0.88-$0.99FY 202419-$4.21-$3.43-$3.78Q1 20252-$1.02-$0.98-$1.00Q2 20252-$1.05-$1.01-$1.03Q3 20252-$1.08-$0.99-$1.04Q4 20252-$1.02-$0.99-$1.01FY 20258-$4.17-$3.97-$4.07Q1 20261-$1.17-$1.17-$1.17Q2 20261-$1.21-$1.21-$1.21Q3 20261-$1.16-$1.16-$1.16 Viridian Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 2/25/2025(Estimated)------- 11/12/2024--$1.11-$1.15 -$0.04-$1.15$0.08M$0.09M8/8/2024--$0.87-$1.02 -$0.15-$1.02$0.09M$0.07M 5/8/2024Q1 2024-$1.07-$0.79+$0.28-$0.79$0.09M$0.07M 2/27/2024Q4 2023-$0.98-$1.35 -$0.37-$1.35$0.15M$0.07M 11/13/2023Q3 2023-$1.22-$1.09+$0.13-$1.09$0.28M$0.07M 8/8/2023Q2 2023-$1.26-$1.27 -$0.01-$1.27$0.25M$0.07M Get the Latest News and Ratings for VRDN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/9/2023Q1 2023-$1.00-$1.61 -$0.61-$1.61$0.10M$0.10M 3/8/2023Q4 2022-$0.72-$1.13 -$0.41-$1.13$0.46M$0.11M Viridian Therapeutics Earnings - Frequently Asked Questions When is Viridian Therapeutics's earnings date? Viridian Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates. Learn more on VRDN's earnings history. Did Viridian Therapeutics beat their earnings estimates last quarter? In the previous quarter, Viridian Therapeutics (NASDAQ:VRDN) missed the analysts' consensus estimate of ($1.11) by $0.04 with a reported earnings per share (EPS) of ($1.15). Learn more on analysts' earnings estimate vs. VRDN's actual earnings. How much revenue does Viridian Therapeutics generate each year? Viridian Therapeutics (NASDAQ:VRDN) has a recorded annual revenue of $310,000.00. How much profit does Viridian Therapeutics generate each year? Viridian Therapeutics (NASDAQ:VRDN) has a recorded net income of -$237.73 million. VRDN has generated -$4.31 earnings per share over the last four quarters. What is Viridian Therapeutics's EPS forecast for next year? Viridian Therapeutics's earnings are expected to decrease from ($4.01) per share to ($4.28) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Arrowhead Pharmaceuticals Earnings OpGen Earnings Psychemedics Earnings PACS Group Earnings Hims & Hers Health Earnings Sotera Health Earnings Option Care Health Earnings Surgery Partners Earnings BrightSpring Health Services Earnings Guardant Health Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for Investors 2024's Must-Watch Stocks! (Ad)Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] This page (NASDAQ:VRDN) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
